Weight-Loss Drugmaker Carmot Therapeutics Is Considering IPO

Weight-loss drugmaker Carmot Therapeutics is exploring an initial public offering, according to people with knowledge of the matter.

The Berkeley, California-based biotechnology company is working with underwriters including JPMorgan Chase & Co. and Bank of America Corp. on a listing that would likely take place next year, though plans could be accelerated if market conditions allow, said the people, who asked not to be identified because the information is private.